A. M. Zeidan Et Al. , "Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)," 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) , vol.140, Louisiana, United States Of America, pp.2063-2065, 2022
Zeidan, A. M. Et Al. 2022. Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS). 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) , (Louisiana, United States Of America), 2063-2065.
Zeidan, A. M., Ando, K., Rauzy, O., Turgut, M., Wang, M., Cairoli, R., ... Hou, H.(2022). Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) . 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) (pp.2063-2065). Louisiana, United States Of America
Zeidan, Amer Et Al. "Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)," 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, United States Of America, 2022
Zeidan, Amer M. Et Al. "Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)." 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) , Louisiana, United States Of America, pp.2063-2065, 2022
Zeidan, A. M. Et Al. (2022) . "Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)." 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) , Louisiana, United States Of America, pp.2063-2065.
@conferencepaper{conferencepaper, author={Amer M. Zeidan Et Al. }, title={Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)}, congress name={64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)}, city={Louisiana}, country={United States Of America}, year={2022}, pages={2063-2065} }